-
公开(公告)号:US20050192278A1
公开(公告)日:2005-09-01
申请号:US11015876
申请日:2004-12-17
申请人: William Ewing , Guixue Yu , Bruce Ellsworth
发明人: William Ewing , Guixue Yu , Bruce Ellsworth
IPC分类号: C07D487/04 , A61K31/53
CPC分类号: C07D487/04
摘要: The present application describes compounds according to Formula I, pharmaceutical compositions comprising at least one compound according to Formula I and optionally one or more additional therapeutic agents and methods of treatment using the compounds according to Formula I both alone and in combination with one or more additional therapeutic agents. The compounds have the general Formula I including all prodrugs, pharmaceutically acceptable salts and stereoisomers, R1, R2, R3, and R4 are described herein.
摘要翻译: 本申请描述了根据式I的化合物,包含至少一种根据式I的化合物和任选的一种或多种另外的治疗剂的药物组合物和使用根据式I的化合物的治疗方法,其单独和与一种或多种另外的 治疗剂。 化合物具有通式I,其包括所有前药,药学上可接受的盐和立体异构体,R 1,R 2,R 3和R 3, SUP> 4 SUP>。
-
公开(公告)号:US20050171110A1
公开(公告)日:2005-08-04
申请号:US11016198
申请日:2004-12-17
申请人: Guixue Yu , William Ewing , Amarendra Mikkilineni , Annapurna Pendri , Bruce Ellsworth , Philip Sher , Samuel Gerritz , Chongqing Sun , Natesan Murugesan , Ximao Wu
发明人: Guixue Yu , William Ewing , Amarendra Mikkilineni , Annapurna Pendri , Bruce Ellsworth , Philip Sher , Samuel Gerritz , Chongqing Sun , Natesan Murugesan , Ximao Wu
IPC分类号: A61K31/5025 , C07D487/04 , A61K31/503
CPC分类号: C07D487/04
摘要: The present application describes compounds according to Formula I, pharmaceutical compositions comprising at least one compound according to Formula I and optionally one or more additional therapeutic agents and methods of treatment using the compounds according to Formula I both alone and in combination with one or more additional therapeutic agents. The compounds have the general Formula I. including all prodrugs, pharmaceutically acceptable salts and stereoisomers, R1, R2, R3, R4, R5, m and n are described herein.
摘要翻译: 本申请描述了根据式I的化合物,包含至少一种根据式I的化合物和任选的一种或多种另外的治疗剂的药物组合物和使用根据式I的化合物的治疗方法,其单独和与一种或多种另外的 治疗剂。 该化合物具有通式Ⅰ,包括所有前药,药学上可接受的盐和立体异构体,R 1,R 2,R 3,R 3, 本文描述了本领域的技术人员,专利文献4,第5和第5,第m和第n。
-
公开(公告)号:US20050143381A1
公开(公告)日:2005-06-30
申请号:US11016135
申请日:2004-12-17
申请人: Guixue Yu , William Ewing , Amarendra Mikkilineni , Annapurna Pendri , Philip Sher , Samuel Gerritz , Bruce Ellsworth , Gang Wu , Yanting Huang , Chongqing Sun , Natesan Murugesan , Zhengxiang Gu , Ying Wang , Doree Sitkoff , Stephen Johnson , Ximao Wu
发明人: Guixue Yu , William Ewing , Amarendra Mikkilineni , Annapurna Pendri , Philip Sher , Samuel Gerritz , Bruce Ellsworth , Gang Wu , Yanting Huang , Chongqing Sun , Natesan Murugesan , Zhengxiang Gu , Ying Wang , Doree Sitkoff , Stephen Johnson , Ximao Wu
IPC分类号: A61K31/5025 , C07D487/04 , A61K31/503
CPC分类号: C07D487/04
摘要: The present application describes compounds according to Formula I, pharmaceutical compositions comprising at least one compound according to Formula I and optionally one or more additional therapeutic agents and methods of treatment using the compounds according to Formula I both alone and in combination with one or more additional therapeutic agents. The compounds have the general Formula I: including all prodrugs, pharmaceutically acceptable salts and stereoisomers, R1, R2, R3, R6, R7, m and n are described herein.
摘要翻译: 本申请描述了根据式I的化合物,包含至少一种根据式I的化合物和任选的一种或多种另外的治疗剂的药物组合物和使用根据式I的化合物的治疗方法,其单独和与一种或多种另外的 治疗剂。 该化合物具有通式I:包括所有前药,药学上可接受的盐和立体异构体,R 1,R 2,R 3,R 3, 本文描述了SUP 6,R 7,m和n。
-
公开(公告)号:US20060160850A1
公开(公告)日:2006-07-20
申请号:US11334204
申请日:2006-01-18
申请人: Chongqing Sun , William Ewing , Yanting Huang , Annapurna Pendri , Samuel Gerritz , Bruce Ellsworth , Natesan Murugesan
发明人: Chongqing Sun , William Ewing , Yanting Huang , Annapurna Pendri , Samuel Gerritz , Bruce Ellsworth , Natesan Murugesan
IPC分类号: A61K31/47 , C07D215/38 , A61K31/4709
CPC分类号: C07D215/38 , C07D215/48 , C07D401/04 , C07D401/12 , C07D405/12 , C07D417/06
摘要: The present application describes compounds according to Formula I, pharmaceutical compositions comprising at least one compound according to Formula I and optionally one or more additional therapeutic agents and methods of treatment using the compounds according to Formula I both alone and in combination with one or more additional therapeutic agents. The compounds have the general Formula I: including all prodrugs, pharmaceutically acceptable salts and stereoisomers, R1, R2, R3, n, and Z are described herein.
摘要翻译: 本申请描述了根据式I的化合物,包含至少一种根据式I的化合物和任选的一种或多种另外的治疗剂的药物组合物和使用根据式I的化合物的治疗方法,其单独和与一种或多种另外的 治疗剂。 化合物具有通式I:包括所有前药,药学上可接受的盐和立体异构体,R 1,R 2,R 3,N, 和Z。
-
公开(公告)号:US20060287323A1
公开(公告)日:2006-12-21
申请号:US11454324
申请日:2006-06-16
申请人: William Ewing , Yeheng Zhu , Bruce Ellsworth
发明人: William Ewing , Yeheng Zhu , Bruce Ellsworth
IPC分类号: C07D487/04 , A61K31/503
CPC分类号: C07D487/04
摘要: The present application describes compounds according to Formula I, pharmaceutical compositions comprising at least one compound according to Formula I and optionally one or more additional therapeutic agents and methods of treatment using the compounds according to Formula I both alone and in combination with one or more additional therapeutic agents. The compounds have the general Formula I and Formula II: including all prodrugs, pharmaceutically acceptable salts and stereoisomers, R1, R2, R3 and R4 are described herein.
摘要翻译: 本申请描述了根据式I的化合物,包含至少一种根据式I的化合物和任选的一种或多种另外的治疗剂的药物组合物和使用根据式I的化合物的治疗方法,其单独和与一种或多种另外的 治疗剂。 化合物具有通式I和式II:包括所有前药,药学上可接受的盐和立体异构体,R 1,R 2,R 3, 和R 4'在本文中描述。
-
6.
公开(公告)号:US20050014786A1
公开(公告)日:2005-01-20
申请号:US10889274
申请日:2004-07-12
申请人: Chongqing Sun , Doree Sitkoff , William Ewing , Yanting Huang , Bruce Ellsworth , Richard Sulsky
发明人: Chongqing Sun , Doree Sitkoff , William Ewing , Yanting Huang , Bruce Ellsworth , Richard Sulsky
IPC分类号: A61K20060101 , A61K31/47 , A61K31/4709 , C07D215/36 , C07D215/38 , C07D215/48 , C07D401/04 , C07D401/06 , C07D401/12 , C07D405/06 , C07D409/04 , C07D409/06 , C07D409/12 , C07D409/14 , C07D413/12 , C07D413/14 , C07D417/06 , C07D417/12 , C07D453/02 , C07D453/04
CPC分类号: C07D417/06 , C07D215/38 , C07D215/48 , C07D401/04 , C07D401/06 , C07D401/12 , C07D405/06 , C07D409/04 , C07D409/06 , C07D409/12 , C07D409/14 , C07D413/12 , C07D413/14 , C07D417/12
摘要: The invention provides for compounds of formula I wherein the substitutents are as described herein. Further provided are methods of using such compounds for the treatment of eating disorders, metabolic disorders, obesity, cognitive disorders, neurological disorders, pain disorders, inflammation disorders, in the promotion of smoking cessation and for the treatment of other psychiatric disorders Also provided are pharmaceutical compositions containing such compounds and pharmaceutical combinations of the compounds of the invention with other therapeutic agents.
摘要翻译: 本发明提供式I化合物,其中取代基如本文所述。 还提供了使用这些化合物治疗进食障碍,代谢紊乱,肥胖症,认知障碍,神经障碍,疼痛障碍,炎症障碍,促进戒烟和治疗其他精神疾病的方法。 还提供含有这些化合物的药物组合物和本发明化合物与其它治疗剂的药物组合。
-
7.
公开(公告)号:US20070238866A1
公开(公告)日:2007-10-11
申请号:US11764839
申请日:2007-06-19
申请人: Prashant Deshpande , Bruce Ellsworth , Janak Singh , Theodor Denzel , Chiajen Lai , Gerard Crispino , Michael Randazzo , Jack Gougoutas
发明人: Prashant Deshpande , Bruce Ellsworth , Janak Singh , Theodor Denzel , Chiajen Lai , Gerard Crispino , Michael Randazzo , Jack Gougoutas
CPC分类号: C07H23/00 , C07H5/04 , C07H5/06 , C07H7/00 , C07H15/207
摘要: Method for the production of C-aryl glucoside SGLT2 inhibitors useful for the treatment of diabetes and related diseases. and intermediates thereof. The C-aryl glucosides may be complexed with amino acid complex forming reagents.
摘要翻译: 生产用于治疗糖尿病和相关疾病的C-芳基葡萄糖苷SGLT2抑制剂的方法。 及其中间体。 C-芳基葡糖苷可以与形成氨基酸复合物的试剂络合。
-
公开(公告)号:US07057046B2
公开(公告)日:2006-06-06
申请号:US10440851
申请日:2003-05-19
申请人: Philip Sher , Gang Wu , Terry Stouch , Bruce Ellsworth
发明人: Philip Sher , Gang Wu , Terry Stouch , Bruce Ellsworth
IPC分类号: C07D403/12 , C07D471/04 , C07D491/048 , C07D495/04 , C07D519/00
CPC分类号: C07D401/12 , A61K31/496 , A61K31/5377 , A61K31/541 , A61K45/06 , C07D209/42 , C07D403/12 , C07D403/14 , C07D413/12 , C07D417/12 , C07D471/04 , C07D513/04 , A61K2300/00
摘要: A compound of formula I wherein W is a bicyclic hetroaryl of the structure X is —O—, —S—, —SO2—, —CHR5—, —CHR5O—, —CHR5S—, —CHR5SO2—, —CHR5CO— or —CH2CHR5—; Y is a bond or —CHR6—; Z is an aryl or heteroaryl group of the following structure: A is —CH— or —N—; B is —O— or —S—; and R1, R2, R3, R4, R5, R6, R7 and R8 are as described herein. Further provided is a method for treating diabetes and related diseases employing a glycogen phosphorylase inhibiting amount of the above compound, either alone or in combination with another therapeutic agent.
摘要翻译: 其中W是结构X的双环杂芳基的式I化合物是-O - , - S - , - SO 2 - , - CHR 5 - , - CHR 5,O-,-CHR 5 S,-CHR 5 SO 2 - , - CHR - 5 CO-或-CH 2 CHR 5 - ; Y是键或-CHR 6 - 。 Z是具有以下结构的芳基或杂芳基:A是-CH-或-N-; B是-O-或-S-; 和R 1,R 2,R 3,R 4,R 5, R 6,R 7和R 8如本文所述。 还提供了单独或与另一种治疗剂组合使用上述化合物的糖原磷酸化酶抑制量的糖尿病和相关疾病的治疗方法。
-
公开(公告)号:US06936590B2
公开(公告)日:2005-08-30
申请号:US10264410
申请日:2002-10-04
申请人: William N. Washburn , Bruce Ellsworth , Wei Meng , Gang Wu , Philip M. Sher
发明人: William N. Washburn , Bruce Ellsworth , Wei Meng , Gang Wu , Philip M. Sher
IPC分类号: A61K31/70 , A61K31/7052 , A61K45/06
CPC分类号: A61K45/06 , A61K31/70 , A61K31/7052 , A61K2300/00
摘要: A method is provided for treating diabetes and related diseases employing an SGLT2 inhibiting amount of a compound of the formula alone or in combination with one or more other antidiabetic agent(s) or other therapeutic agent(s).
摘要翻译: 提供了一种用于治疗糖尿病和相关疾病的方法,其使用抑制SGLT2的量的单独的化合物或与一种或多种其它抗糖尿病剂或其它治疗剂组合。
-
公开(公告)号:US07425550B2
公开(公告)日:2008-09-16
申请号:US11352867
申请日:2006-02-13
申请人: Philip Sher , Gang Wu , Terry Stouch , Bruce Ellsworth
发明人: Philip Sher , Gang Wu , Terry Stouch , Bruce Ellsworth
IPC分类号: A61K31/554 , C07D267/14 , C07D498/02
CPC分类号: C07D401/12 , A61K31/496 , A61K31/5377 , A61K31/541 , A61K45/06 , C07D209/42 , C07D403/12 , C07D403/14 , C07D413/12 , C07D417/12 , C07D471/04 , C07D513/04 , A61K2300/00
摘要: A compound of formula I is provided having the structure wherein W is as defined herein; X is —CHR5O—; Y is a bond; Z is an aryl or heteroaryl group; and R1, and R2, are as described herein. Further provided is a method for treating diabetes and related diseases employing the above compound, either alone or in combination with another therapeutic agent.
摘要翻译: 提供具有其中W如本文所定义的结构的式I化合物; X是-CHR 5 O-; Y是一个债券; Z是芳基或杂芳基; 和R 1,R 2和R 2如本文所述。 还提供了使用上述化合物单独或与其它治疗剂组合治疗糖尿病和相关疾病的方法。
-
-
-
-
-
-
-
-
-